STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 89 filers reported holding STOKE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $93,185 | -67.1% | 23,651 | -11.3% | 0.00% | – |
Q2 2023 | $283,417 | +53.5% | 26,662 | +20.3% | 0.00% | – |
Q1 2023 | $184,626 | -12.7% | 22,164 | -3.3% | 0.00% | – |
Q4 2022 | $211,542 | -26.3% | 22,919 | +2.5% | 0.00% | – |
Q3 2022 | $287,000 | -1.4% | 22,350 | +1.3% | 0.00% | – |
Q2 2022 | $291,000 | -28.0% | 22,056 | +15.0% | 0.00% | -100.0% |
Q1 2022 | $404,000 | -20.9% | 19,181 | -10.0% | 0.00% | 0.0% |
Q4 2021 | $511,000 | -3.6% | 21,313 | +2.3% | 0.00% | 0.0% |
Q3 2021 | $530,000 | -40.2% | 20,830 | -20.9% | 0.00% | 0.0% |
Q2 2021 | $887,000 | +11.6% | 26,337 | +28.7% | 0.00% | 0.0% |
Q1 2021 | $795,000 | -31.6% | 20,463 | +9.1% | 0.00% | -50.0% |
Q4 2020 | $1,162,000 | +88.3% | 18,764 | +1.9% | 0.00% | +100.0% |
Q3 2020 | $617,000 | +40.5% | 18,420 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $439,000 | -25.8% | 18,420 | -28.8% | 0.00% | 0.0% |
Q1 2020 | $592,000 | +46.5% | 25,853 | +81.2% | 0.00% | 0.0% |
Q4 2019 | $404,000 | +31.6% | 14,264 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $307,000 | – | 14,264 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 296,822 | $9,991,000 | 2.07% |
RTW INVESTMENTS, LP | 3,644,248 | $122,665,000 | 1.85% |
Cormorant Asset Management, LP | 1,278,276 | $43,027,000 | 1.46% |
Redmile Group, LLC | 2,458,558 | $82,755,000 | 1.22% |
SPHERA FUNDS MANAGEMENT LTD. | 233,135 | $7,847,000 | 0.53% |
Birchview Capital, LP | 15,000 | $505,000 | 0.30% |
Perceptive Advisors | 1,343,956 | $45,238,000 | 0.29% |
GILDER GAGNON HOWE & CO LLC | 1,245,956 | $41,939,000 | 0.21% |
Artal Group S.A. | 250,000 | $8,415,000 | 0.17% |
Casdin Capital, LLC | 120,000 | $4,039,000 | 0.10% |